- Conditions
- Neoplasm Metastases, Hepatic Insufficiency
- Interventions
- Trabectedin, Dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Detroit, Michigan • New York, New York + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 3,978
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Failure, Left Ventricular Dysfunction
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Bethesda, Maryland
- Conditions
- Aging, Endothelial Dysfunction, Senescence
- Interventions
- COMP-4
- Dietary Supplement
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Anxiety, Pain, Surgery
- Interventions
- Galacto-Oligosaccharide, Maltodextrin (Placebo)
- Drug
- Lead sponsor
- Jeff Taekman, M.D.
- Other
- Eligibility
- 21 Years to 70 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Executive Dysfunction, Depression
- Interventions
- Intermittent Theta Burst Stimulation, sham stimulation
- Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Acute-On-Chronic Liver Failure, Ascites
- Interventions
- VS-01 on top of SOC, SOC (Control Group)
- Drug · Other
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 13
- States / cities
- Sacramento, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more
- Conditions
- Depression, Anxiety, Cognitive Impairment
- Interventions
- Not listed
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 1,206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Breast Cancer, Metastatic Triple-Negative Breast Cancer
- Interventions
- Eribulin, SDX-7320, Placebo
- Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 10
- States / cities
- Miami, Florida • Atlanta, Georgia • Basking Ridge, New Jersey + 7 more
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Lou Gehrig Disease
- Interventions
- Not listed
- Lead sponsor
- Barrow Neurological Institute
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Progressive Supranuclear Palsy
- Interventions
- Radiopharmaceuticals
- Drug
- Lead sponsor
- University of California, Berkeley
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Berkeley, California
- Conditions
- Disability Physical, Cognitive Impairment
- Interventions
- Modified FE-SaLiR, Unmodified Chinese Medicine Exercise, Active Control
- Behavioral
- Lead sponsor
- The University of Texas at San Antonio
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Mild Cognitive Impairment
- Interventions
- Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation (Sham)
- Device
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Dementia Alzheimers, Dementia, Memory Impairment, NPS
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Quercetin, Acarbose, placebo
- Dietary Supplement · Drug
- Lead sponsor
- Bastyr University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Decompression Sickness, Endothelial Dysfunction, Neutrophil Activation, Venous Gas Emboli
- Interventions
- Aerobic running exercise
- Other
- Lead sponsor
- University of Split
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
- Interventions
- Survodutide, Placebo
- Combination Product
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 165
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Scottsdale, Arizona + 132 more
- Conditions
- Bipolar Disorder
- Interventions
- Galantamine-CR
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2006
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Nausea, Anxiety
- Interventions
- Inhaled Essential Oils, Wearable TENS Device
- Other · Device
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
- Interventions
- vorinostat, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 11
- States / cities
- Duarte, California • Los Angeles, California • Atlanta, Georgia + 8 more
- Conditions
- Vasodilation, Arterial Stiffness
- Interventions
- Acetylcholine, Sodium Nitroprusside, Ascorbic Acid
- Drug
- Lead sponsor
- Colorado State University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Vaginal Atrophy, Sexual Dysfunction, Vaginal Dryness, Dyspareunia
- Interventions
- Hybrid Fractional Laser
- Device
- Lead sponsor
- Sciton
- Industry
- Eligibility
- 40 Years to 70 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Cognitive Impairment
- Interventions
- No Interventions as this is a observational study
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Interventions
- TRE plus SOC, SOC, TRE
- Behavioral
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer, Erectile Dysfunction
- Interventions
- Placebo, Erythropoietin (EPO)
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 40 Years to 65 Years · Male only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland